Phosphodiesterase 4 inhibitors

US7235579B2 · kind B2 · utility

Assignee

• Memory Pharmaceuticals Corporation · US

Inventors

• Ruiping Liu · Beijing, CN
• Mike De Vivo · New York, US
• Hans-Jurgen E. Hess · Old Lyme, US
• Allen Hopper · Glen Rock, US
• Erik Kuester · Rochester, US
• Ashok Tehim · Ridgewood, US

Key dates

• Filing date: Oct 16, 2002
• Grant date: Jun 26, 2007
• Expiry date: Sep 29, 2023

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Selective PDE4 inhibition is achieved by 4-(substituted-phenyl)-2-pyrrolidinone compounds. The compounds exhibit improved PDE4 inhibition as compared to compounds like rolipram and show selectivity with regard to inhibition of other classes of PDEs. The compounds of the present invention are of formula I: wherein R1, R2, and R3 are as defined herein.